Friday, March 20, 2015 9:18:34 AM
Unexpected cardiotoxicity, which damages the heart muscles, is among the most prevalent reasons for failure of both drugs and drug candidates. VistaGen Therapeutics, Inc. (OTCQB: VSTA), through its customized cellular assay system, CardioSafe 3D™, is working to enhance current testing practices and dramatically improve clinical predictability for new drugs.
The company’s CardioSafe 3D™ technology utilizes VistaGen’s human pluripotent stem cell-derived cardiomyocytes (hPSC-CM) and customized assays to screen for heart complications of new drug candidates, including cardiomyocyte cytotoxicity and the development of irregular beating patterns. By incorporating its groundbreaking system early in preclinical development, VistaGen expects to decrease development costs by avoiding instances of late-stage clinical termination and product recall from the market.
With its proprietary human stem cell differentiation technology, the company is able to generate hPSC-CMs at higher levels of purity without the need for genetic modification or cell selection, which can distort results and clinical predictively. VistaGen expects CardioSafe 3D™ to be effective as both a method of identifying novel drug candidates with potential cardiotoxicity side effects and a new generation tool to study important potential mechanisms of cardiotoxicity for drug discovery and regenerative medicine applications.
According to a report from The National Center for Biotechnology Information (NCBI), cardiovascular toxicity remains a major cause of concern for a variety of drug candidates, including those used to treat various types of cancer, antidepressants, antipsychotics and antibiotics. Current testing methods, such as live animal models and the hERG assay, simply can’t provide the far more comprehensive levels of human biological accuracy needed to prevent potentially costly oversights in drug development.
NCBI reports that the costs associated with bringing a new drug to market exceed $1.5 billion, and experts agree that the cost of research and development, particularly in terms of clinical trials, is still on the rise. For that reason, it’s imperative for pharmaceutical companies to use the most accurate tools available in order to avoid potentially massive financial missteps. VistaGen, through the continued development and implementation of its CardioSafe 3D™ technology, is creating a preclinical tool that major pharmaceutical developers and the FDA won’t be able to ignore.
For more information on the company, visit www.vistagen.com
Recent VTGN News
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue • Business Wire • 04/25/2024 12:30:00 PM
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference • Business Wire • 04/09/2024 12:30:00 PM
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 • Business Wire • 04/01/2024 12:30:00 PM
- Vistagen to Present at Stifel 2024 Virtual CNS Days • Business Wire • 03/11/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:10 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/01/2024 05:15:07 AM
- Vistagen to Present at TD Cowen 44th Annual Health Care Conference • Business Wire • 02/28/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:18:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:51:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:56:03 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/13/2024 09:52:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:33:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:25:18 PM
- Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update • Business Wire • 02/13/2024 09:20:00 PM
- Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024 • Business Wire • 02/06/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:19:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:17:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:09:52 PM
- Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain • Business Wire • 12/27/2023 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:44:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:42:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM